title: A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapy.
abstract: OBJECTIVE
  Patients with malignant lung cancer often develop a solitary pulmonary nodule after treatment of the initial cancer. In those cases, it is difficult to distinguish primary lung cancer (PLC) from lung metastasis. Therefore, both local therapy for a single lung lesions and systemic therapy for micrometastases are needed. This retrospective study aimed to evaluate the safety and tolerability of concurrent stereotactic body radiation therapy (SBRT) and chemotherapy in patients with metachronous PLC.
  
  
  METHODS
  We reviewed the records of 10 patients with metachronous PLC treated with SBRT and concurrent chemotherapy with curative intent from 2007 to 2013. The delivered radiation dose was 48 Gy in four fractions.
  
  
  RESULTS
  All patients received SBRT with concurrent chemotherapy on schedule. Complete response rate was 90%. Safety profile of this treatment was compatible with that of traditional chemoradiotherapy.
  
  
  CONCLUSIONS
  Our study showed good feasibility and safety for SBRT with concurrent chemoradiotherapy.
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan jumpeinr2tfm3@fbri.org.
authors.forename: Jumpei
authors.initials: J
authors.lastname: Takeshita
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Masago
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kato
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Otsuka
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Chiyuki
authors.initials: C
authors.lastname: Okuda
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Akito
authors.initials: A
authors.lastname: Hata
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Reiko
authors.initials: R
authors.lastname: Kaji
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Shiro
authors.initials: S
authors.lastname: Fujita
authors.affiliation: Division of Radiation Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Takayama
authors.affiliation: Division of Radiation Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Kokubo
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Katakami
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D016634:Radiosurgery / Q000009:adverse effects
keywords: Non-small cell lung cancer; inoperable; metachronous; platinum doublets; stage I